Main research interests are in neurodegeneration and are focussed on the molecular pathogenesis of Parkinson’s disease (PD) and in the development of drugs for slowing the progress of this disease. Basic science expertise includes mitochondrial biology, and his group was the first to identify mitochondrial abnormalities as a contributing factor to the pathogenesis of Parkinson’s disease. He direct a large group investigating the interaction of PINK1, parkin and alpha synuclein mutations in PD and how these lead to neuronal dysfunction and death, and the biochemical relationship between glucocerebrosidase mutations and an increased risk for PD. His clinical research is focussed on PD and encompasses both symptomatic and disease modifying therapies. Principal investigator on several international clinical trials in the development of novel symptomatic treatments for PD and neuroprotection studies. Currently leading research on the clinical phenotype of patients at risk of developing PD including those with glucocerebrosidase mutations. This work is designed to identify clinical and biochemical features of prodromal PD. Co-Principal Investigator on the MRC-Wellcome Strategic Award in Neurodegeneration (6 million) and on the Wolfson Award (£20 million)